BR100 Increased By (0.01%)
BR30 Decreased By (-1.15%)
KSE100 Increased By (0.09%)
KSE30 Decreased By (-0.05%)
AGHA 6.02 Decreased By ▼ -0.03 (-0.5%)
BECO 3.81 Decreased By ▼ -0.02 (-0.52%)
BML 56.44 Decreased By ▼ -1.89 (-3.24%)
BOP 28.10 Decreased By ▼ -0.25 (-0.88%)
CNERGY 12.28 Decreased By ▼ -1.36 (-9.97%)
CSIL 5.29 Increased By ▲ 0.08 (1.54%)
FCCL 53.81 Increased By ▲ 1.53 (2.93%)
FFL 12.80 Decreased By ▼ -0.10 (-0.78%)
FNEL 1.12 Decreased By ▼ -0.01 (-0.88%)
KEL 5.64 Decreased By ▼ -0.15 (-2.59%)
KOSM 5.38 Decreased By ▼ -0.13 (-2.36%)
LOTCHEM 23.55 Decreased By ▼ -0.34 (-1.42%)
MLCF 91.96 Increased By ▲ 1.45 (1.6%)
NBP 162.24 Increased By ▲ 2.52 (1.58%)
NCPL 48.91 Decreased By ▼ -0.69 (-1.39%)
NPL 50.51 Decreased By ▼ -1.29 (-2.49%)
OGDC 301.68 Decreased By ▼ -5.10 (-1.66%)
PACE 9.13 Decreased By ▼ -0.02 (-0.22%)
PAEL 31.81 Decreased By ▼ -0.52 (-1.61%)
PIBTL 12.78 Decreased By ▼ -0.15 (-1.16%)
PPL 212.06 Decreased By ▼ -1.87 (-0.87%)
PRL 87.26 Decreased By ▼ -9.70 (-10%)
PTC 43.96 Decreased By ▼ -1.23 (-2.72%)
SSGC 22.86 Increased By ▲ 0.33 (1.46%)
TBL 8.91 Decreased By ▼ -0.11 (-1.22%)
TELE 6.44 Decreased By ▼ -0.28 (-4.17%)
TPL 24.09 Decreased By ▼ -1.82 (-7.02%)
TPLP 12.16 Decreased By ▼ -0.44 (-3.49%)
TREET 23.50 Increased By ▲ 0.04 (0.17%)
TRG 51.87 Decreased By ▼ -0.09 (-0.17%)
World

Britain probing AstraZeneca-Alexion deal over competition concerns

  • The Competition and Markets Authority said it was inviting comments from any interested party on the deal to help with its assessment. It has set a deadline of June 3 for the insight from any stakeholders.
Published Updated
By

Britain's competition regulator said on Tuesday it has started a probe into AstraZeneca's $39 billion takeover of US drugmaker Alexion for possibly reducing competition in the UK market or elsewhere.

The Competition and Markets Authority said it was inviting comments from any interested party on the deal to help with its assessment. It has set a deadline of June 3 for the insight from any stakeholders.

Anglo-Swedish drugmaker AstraZeneca agreed to buy Alexion in December in its largest ever deal, diversifying away from its fast-growing cancer business in a bet on rare-disease and immunology drugs.

Comments

Comments are closed for this article.